Semax (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Semax is a synthetic heptapeptide derived from the ACTH(4–10) fragment, extended at the C-terminus with a Pro-Gly-Pro tripeptide that slows enzymatic breakdown. The numbers below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration every 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers 100 mcg of material, which keeps the arithmetic clean across the low microgram steps typical of this peptide.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation pattern used in educational nootropic protocols, where the daily amount is stepped up roughly every two weeks while tolerability and response are observed.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Extended) Schedule

Some educational protocols hold the upper 800 mcg daily step and extend the cycle beyond eight weeks, inserting an off-period to limit continuous exposure. The 30 mg fill comfortably supports this longer run because of its large total payload.

Supplies Needed

• Semax vials (30 mg): 1 vial covers a full 8-week gradual cycle; ~2 vials for a 12–16 week extended run.
• Insulin syringes (U-100, 1 mL): ~56 for an 8-week daily schedule; ~84–112 for a 12–16 week run (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle reconstitutes several vials; a single bottle covers a standard cycle.
• Alcohol swabs: a 100-count box covers an 8-week schedule; two boxes for an extended run.

Protocol Overview

• Research goal: model neuroprotective and nootropic activity via ACTH(4–10) fragment signalling.
• Route: subcutaneous or intranasal in the published models.
• Schedule: once-daily administration.
• Dose band: 300–800 mcg daily.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 300 mcg step and hold each level for roughly two weeks before escalating.
• Keep administration on a fixed daily cadence, ideally at the same time, for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Standard educational cycles run eight weeks continuously; longer runs add a planned off-period.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Because per-dose volumes are very small (3–8 units), draw slowly and check for air bubbles before measuring.
• Document each draw — date, volume, remaining material — for reproducibility.

How Semax Works

Semax is a synthetic heptapeptide analog of the ACTH(4–10) sequence, carrying a C-terminal Pro-Gly-Pro extension that markedly improves its resistance to peptidase degradation relative to the native fragment. In the published literature it is associated with up-regulation of brain-derived neurotrophic factor (BDNF) and its receptor, alongside modulation of cholinergic and dopaminergic neurotransmission. Unlike the parent ACTH fragment, it lacks meaningful corticotropic activity, so it does not appreciably raise cortisol. These mechanisms underlie its study as a neuroprotective and cognition-modulating agent.

Reported Benefits & Side Effects

Benefits observed in research

• Signals of improved attention, memory consolidation and learning in populations with cognitive deficits.
• Studied as a neuroprotective adjunct in ischemic stroke and traumatic brain injury models.
• Evaluated in optic neuropathy and other neurological conditions with favourable safety reports.
• Antioxidant and anti-inflammatory effects described in preclinical work.

Side effects reported

• Generally well tolerated across the available studies.
• Intranasal administration: occasional minor nasal irritation.
• Subcutaneous administration: mild injection-site reactions such as redness or itching.
• No significant elevations in cortisol or other adverse endocrine effects reported.

Injection/Handling Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• For subcutaneous work, insert at a 45–90° angle depending on needle length; aspiration is not required.
• For the intranasal route described in the literature, the solution is measured the same way and the small volume is divided between nostrils.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols